Disease biology is heterogeneous, but most research reduces it to group means
NEW WORK characterizing HETEROGENEITY in BRAIN and BIOCHEMICAL biomarkers across >1/2 million people & >30 disorders:
https://t.co/lNfZH48hTJ
Check out the online resource:
https://t.co/azWezh0mAe
for building a more coherent and clinically meaningful evidence base. In essence, the CAS-BD project offers a roadmap for what to measure next, moving us closer to standardised cognitive endpoints that better reflect everyday social and emotional functioning.
Happy to share a paper I led alongside a small working group of colleagues as part of ISBD Targeting Cognition Taskforce: “Consensus on Subdomains and Measures of Relevance to Affective and Social Cognition Research on Bipolar Disorder (CAS‑BD)”, https://t.co/1HEcCu7qGW
For researchers & clinicians working on cognition &/or interventions in bipolar disorder, the CAS‑BD project offers a practical framework with clearer definitions of affective and social cognition in BD, guidance on which domains to prioritise, & an initial toolkit
We are launching the Catherine Medalia Johannet memorial prize for best Early Career or Lived Experience paper in Cognitive Rehabilitation. Please see the link and share with relevant colleagues: https://t.co/SN2IO3XgCf
➡️ Bipolar disorder (BD) is a chronic and recurrent mood disorder, and among the leading causes of disability because of its negative impact on functioning and high mortality.
➡️ Careful clinical assessment is crucial to ensure accurate diagnosis and treatment.
➡️ The treatment of BD involves acute treatment, which alleviates immediate symptoms, followed by maintenance treatment aimed at preventing the recurrence of mood disturbances.
Our educational slide decks on this complex condition provide an introduction to BD as a heterogeneous disorder, illustrated by its symptoms, comorbidities, and treatment responses of individual patients.
Follow the link to access free educational slide decks, illustrations, and expert videos on the topic: https://t.co/pAvFTEYTZG
The Australasian COgnitive Recovery in Mental Health Network (ACORN) website is now live. ACORN is a collaborative network dedicated to improving cognitive health outcomes for people experiencing mental illness across Australasia. Check it out here: https://t.co/YFfD3a0JqW
Prescribing or taking lithium + starting a GLP-1 agonist?
⚠️ Monitor lithium levels closely—GLP-1s may alter absorption and clearance.
#PsychiatryPearls#GLP1#LithiumSafety
We're excited to share that ACORN is hosting another webinar. The webinar will be presented by Prof Amy Pinkham and is focused on social cognition in schizophrenia and related conditions. Scan the QR code or follow the link below to find out more
https://t.co/Pw3brpY2Sy